Open

Combination of XL092 and Cemiplimab in Anaplastic Thyroid Cancer

The purpose of this study is to look at the effectiveness of giving cemiplimab and XL092 before and after surgery for Anaplastic Thyroid Cancer.

Age & Gender

18 years ~ 99 years
Male, Female, Gender Inclusive

Visit Availability

Standard business hours (M-F, 8-5)

Location

United States (Nationwide)

What will be asked of you

You will meet with the study team to determine if you are eligible for this study. The study team will review your medical history, exam, imaging, and labs. If you do not have archived tissue, you will need to have a tissue biopsy. If you are eligible for the study, you will start your treatment with the two study drugs (XL092 and cemiplimab). You will have surgery to remove your cancer. You may have radiation therapy, if the study team thinks it would help. After this, you will continue to take XL092 and cemiplimab for up to 2 years. After you finish treatment, you will follow up with your clinical team for up to 5 years.

In-person visits:
15+

Total length of participation:
5 years and 8 months

Looking for Specific Volunteers

Able to participate:

Diagnosis of Anaplastic Thyroid Cancer
Have archived tissue or is willing to have a tissue biopsy before starting treatment
Have BRAF V600E mutation in tumor
Have resectable, unresectable disease, or oligometastatic disease
Have adequate lab values per protocol

Not eligible if:

Pregnant or breastfeeding
Ongoing or recent significant autoimmune disease that requires treatment
Uncontrolled incurrent illness, such as active infection, congestive heart failure, uncontrolled hypertension, interstitial lung disease
Have clinically significant heart disease
Known infection of hepatitis B or C, HIV, or AID-related illness

Contact the Team

Visit Location

Contact & Visit Location

Primary Contact

Lineberger Clinical Research
cancerclinicaltrials@med.unc.edu

Primary Visit Location

NC Cancer Hospital (Basnight)
UNC Hospitals / UNC Medical Center
101 Manning Dr, Chapel Hill, NC 27514, USA

Additional Study Information

Principal Investigator

Sid Sheth
LCCC - Clinical Trials

Study Type

Clinical or Medical
Interventional

Study Topics

Cancer (Thyroid and Other Gland/Endocrine)

IRB Number

24-3051

Copyright © 2013-2022 The NC TraCS Institute, the integrated home of the NIH Clinical and Translational Science Awards (CTSA) Program at UNC-CH. This website is made possible by CTSA Grant UL1TR002489 and the National Center for Advancing Translational Sciences.

Helpful Links

Questions?

This email address is being protected from spambots. You need JavaScript enabled to view it.